Seite - 67 - in Cancer Nanotheranostics - What Have We Learnd So Far?

MorenoandPêgo AONcancer therapeutics complexation. Biochim. Biophys. Acta 1568, 177–182. doi: 10.1016/S0304- 4165(01)00216-1 Minshull, J., andHunt,T. (1986).Theuseof single-strandedDNAandRNaseHto promote quantitative “hybrid arrest of translation”ofmRNA/DNAhybrids in reticulocyte lysate cell-free translations.Nucleic Acids Res. 14, 6433–6451. doi: 10.1093/nar/14.16.6433 Mocanu, J.D.,Yip,K.W.,Skliarenko, J.,Shi,W.,Busson,P.,Lo,K.W.,etal. (2007). Imagingandmodulatingantisensemicrodistribution insolidhumanxenograft tumormodels.Clin.CancerRes.13, 5935–5941. doi: 10.1158/1078-0432.CCR- 06-3085 Monia, B. P., Lesnik, E. A., Gonzalez, C., Lima,W. F., McGee, D., Guinosso, C. J., etal. (1993).Evaluationof2′-modifiedoligonucleotidescontaining2′-deoxy gapsasantisenseinhibitorsofgeneexpression. J.Biol.Chem.268,14514–14522. Mou, T. C., Gray, C. W., Terwilliger, T. C., and Gray, D. M. (2001). Ff gene 5 proteinhasahighbindingaffinity for single-strandedphosphorothioateDNA. Biochemistry40,2267–2275.doi:10.1021/bi002136f Nakamura,H.,Oda, Y., Iwai, S., Inoue,H.,Ohtsuka, E., Kanaya, S., et al. (1991). HowdoesRNaseHrecognizeaDNA.RNAhybrid?Proc.Natl.Acad. Sci.U.S.A. 88,11535–11539.doi:10.1073/pnas.88.24.11535 Netti,P.A.,Berk,D.A.,Swartz,M.A.,Grodzinsky,A.J.,andJain,R.K.(2000).Role ofextracellularmatrixassembly in interstitial transport insolid tumors.Cancer Res.60,2497–2503. Nielsen,P.E.,Egholm,M.,Berg,R.H.,andBuchardt,O.(1991).Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide.Science254,1497–1500.doi:10.1126/science.1962210 Nishizaki,T., Iwai,S.,Ohtsuka,E.,andNakamura,H.(1997).Solutionstructureof anRNA.2′-O-methylatedRNAhybridduplex containinganRNA.DNAhybrid segmentat thecenter.Biochemistry36,2577–2585.doi:10.1021/bi962297c Obika, S., Nanbu, D., Hari, Y., Andoh, J.-I., Morio, K.-I., Doi, T., et al. (1998). Stability and structural features of the duplexes containing nucleoside ana- logueswithafixedN-typeconformation,2′-O,4′-C-methyleneribonucleosides. TetrahedronLett.39,5401–5404.doi:10.1016/S0040-4039(98)01084-3 Pasternak, A., and Wengel, J. (2011). Unlocked nucleic acid–an RNA mod- ification with broad potential. Org. Biomol. Chem. 9, 3591–3597. doi: 10.1039/c0ob01085e Plenat, F., Klein-Monhoven, N., Marie, B., Vignaud, J. M., and Duprez, A. (1995). Cell and tissue distribution of synthetic oligonucleotides in healthy and tumor-bearingnudemice.Anautoradiographic, immunohistological, and directfluorescencemicroscopystudy.Am.J.Pathol.147,124–135. Senn, J. J., Burel, S., and Henry, S. P. (2005). Non-CpG-containing antisense 2′-methoxyethyl oligonucleotides activate a proinflammatory response inde- pendentofToll-likereceptor9ormyeloiddifferentiationfactor88.J.Pharmacol. Exp.Ther.314,972–979.doi:10.1124/jpet.105.084004 Seong, J. H., Lee, K. M., Kim, S. T., Jin, S. E., and Kim, C. K. (2006). Polyethylenimine-based antisense oligodeoxynucleotides of IL-4 suppress the production of IL-4 in amurinemodel of airway inflammation. J. GeneMed. 8,314–323.doi:10.1002/jgm.848 Simoes, S., Filipe, A., Faneca, H., Mano, M., Penacho, N., Duzgunes, N., et al. (2005). Cationic liposomes for gene delivery. Expert Opin. Drug Deliv. 2, 237–254.doi:10.1517/17425247.2.2.237 Srinivasan, S. K., Tewary, H. K., and Iversen, P. L. (1995). Characterization of binding sites, extentofbinding, anddrug interactionsofoligonucleotideswith albumin.AntisenseRes.Dev.5,131–139. Stanton, R., Sciabola, S., Salatto, C., Weng, Y., Moshinsky, D., Little, J., et al. (2012). Chemicalmodification study of antisense gapmers.Nucleic Acid Ther. 22,344–359.doi:10.1089/nat.2012.0366 Stein,C.A.,Hansen, J. B., Lai, J.,Wu, S.,Voskresenskiy,A.,Hog,A., et al. (2010). Efficient gene silencing by delivery of locked nucleic acid antisense oligonu- cleotides, unassisted by transfection reagents.Nucleic Acids Res. 38, e3. doi: 10.1093/nar/gkp841 Stessl,M.,Marchetti-Deschmann,M.,Winkler, J.,Lachmann,B.,Allmaier,G., and Noe, C. R. (2009). A proteomic study reveals unspecific apoptosis induction andreductionofglycolyticenzymesbythephosphorothioateantisenseoligonu- cleotideoblimerseninhumanmelanomacells. J.Proteomics72,1019–1030.doi: 10.1016/j.jprot.2009.06.001 Stewart,A. J.,Pichon,C.,Meunier,L.,Midoux,P.,Monsigny,M., andRoche,A.C. (1996). Enhanced biological activity of antisense oligonucleotides complexed withglycosylatedpoly-L-lysine.Mol.Pharmacol.50,1487–1494. Straarup,E.M.,Fisker,N.,Hedtjarn,M.,Lindholm,M.W.,Rosenbohm,C.,Aarup, V., et al. (2010). Short locked nucleic acid antisense oligonucleotides potently reduceapolipoproteinBmRNAandserumcholesterol inmiceandnon-human primates.NucleicAcidsRes.38,7100–7111.doi:10.1093/nar/gkq457 Summerton, J., andWeller, D. (1997). Morpholino antisense oligomers: design, preparation, andproperties.AntisenseNucleicAcidDrugDev.7, 187–195. doi: 10.1089/oli.1.1997.7.187 VanVlerken, L. E., Vyas, T. K., and Amiji,M.M. (2007). Poly(ethylene glycol)- modified nanocarriers for tumor-targeted and intracellular delivery. Pharm. Res.24,1405–1414.doi:10.1007/s11095-007-9284-6 Watanabe, T. A., Geary, R. S., and Levin, A. A. (2006). Plasma protein bind- ing of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides16,169–180.doi:10.1089/oli.2006.16.169 Watts, J.K., andCorey,D.R. (2012). Silencingdiseasegenes in the laboratoryand theclinic. J.Pathol.226,365–379.doi:10.1002/path.2993 Webb,M. S., Tortora,N., Cremese,M., Kozlowska,H., Blaquiere,M.,Devine,D. V., et al. (2001). Toxicity and toxicokinetics of a phosphorothioate oligonu- cleotideagainst thec-myconcogene incynomolgusmonkeys.AntisenseNucleic AcidDrugDev.11,155–163.doi:10.1089/108729001300338681 Winkler, J., Stessl,M.,Amartey, J., andNoe,C.R. (2010).Off-target effects related to the phosphorothioatemodification of nucleic acids.Chem.Med. Chem. 5, 1344–1352.doi:10.1002/cmdc.201000156 Wisse, E., Jacobs, F., Topal, B., Frederik, P., andDeGeest, B. (2008). The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte- directedgene transfer.GeneTher.15,1193–1199.doi:10.1038/gt.2008.60 Wu,X.A.,Choi,C.H.,Zhang,C.,Hao,L., andMirkin,C.A. (2014). Intracellular fate of spherical nucleic acid nanoparticle conjugates. J. Am. Chem. Soc. 136, 7726–7733.doi:10.1021/ja503010a Yin,H., Kanasty, R. L., Eltoukhy,A.A., Vegas, A. J.,Dorkin, J. R., andAnderson, D. G. (2014). Non-viral vectors for gene-based therapy.Nat. Rev. Genet. 15, 541–555.doi:10.1038/nrg3763 Zhang, C., Newsome, J. T.,Mewani, R., Pei, J., Gokhale, P. C., and Kasid, U. N. (2009). Systemicdelivery andpre-clinical evaluationofnanoparticles contain- ingantisenseoligonucleotides and siRNAs.MethodsMol.Biol.480, 65–83.doi: 10.1007/978-1-59745-429-2_5 Zhang,Y.,Qu,Z.,Kim,S.,Shi,V.,Liao,B.,Kraft,P.,etal.(2011).Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonu- cleotideswithouttransfection.GeneTher.18,326–333.doi:10.1038/gt.2010.133 Conflict of Interest Statement:The authors declare that the research was con- ducted in the absence of any commercial or financial relationships that could be construedasapotential conflictof interest. Received: 31August 2014; paperpendingpublished: 10September2014; accepted: 23 September2014;publishedonline:14October2014. Citation:Moreno PMDand Pêgo AP (2014) Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic. Front. Chem. 2:87. doi: 10.3389/fchem. 2014.00087 Thisarticlewas submitted toChemicalEngineering,a sectionof the journalFrontiers inChemistry. Copyright © 2014MorenoandPêgo.This isanopen-accessarticledistributedunder the terms of theCreativeCommonsAttribution License (CCBY). The use, distribu- tion or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permittedwhichdoesnot complywith these terms. www.frontiersin.org October2014 |Volume2 |Article87 | 67